Surgery for Obstructed Gastric Carcinoma

February 24, 2026 updated by: Reham Zakaria Mohamed Ahmed, Zagazig University

Palliative Resection Versus Palliative Bypass in Obstructed Locally Advanced Gastric Carcinoma

The goal of this clinical trial is to find the best treatment for obstructed gastric carcinoma in gastric cancer patients. It will include all patients with obstructed gastric cancer with different ages and sex who consented to share in the trial. The main question is what is the better for management for obstructed gastric cancer; palliative resection or palliative bypass? We hypothesized that resection is better. patients will be divided into two groups. the primary outcome measure will be the relief of obstruction

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

63

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Sharqia Province
      • Zagazig, Sharqia Province, Egypt, 44519
        • Faculty of Medicine, Zagazig University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • emergency obstructed gastric cancer patients

Exclusion Criteria:

  • non obstructed gastric cancer patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group I: obstructed gastric cancer patients
patients presented with emergency gastric obstruction
Procedure: palliative gastric resection
distal, subtotal or total gastrectomy with gastro-jejunostomy or eosphago-jejunostomy will be done
Active Comparator: Group II: obstructed gastric cancer patients
patients presented with emergency gastric obstruction
Procedure: palliative bypass
palliative gastro-jejunostomy or eosphago-jejunostomy will be done

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
upper gastrointestinal symptoms
Time Frame: from one day to two weeks after surgery
upper gastrointestinal symptoms will be evaluated after surgery by Rhodes Index questionnaire. It is a validated, self-report instrument used to measure the intensity, frequency, and distress of upper gastrointestinal symptoms. The scale measures three main areas: nausea (frequency, duration, distress), vomiting (amount, frequency, distress), and retching (frequency, distress). It utilizes a 5-point Likert scale (0-4) to quantify the severity of these symptoms. 0 is the least amount of distress and 4 is the most distress.
from one day to two weeks after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
anastmotic leak
Time Frame: from day one to two weeks after surgery.
anastmotic site leakage will be assessed by abnormal discharge in the drain calculated in cc.
from day one to two weeks after surgery.
ICU admission
Time Frame: from day one to two weeks after surgery
the need of ICU admission will be evaluated by (yes or No)
from day one to two weeks after surgery
wound infection
Time Frame: from day one to one month after surgery
wound infection will be identified by presence of pus in the dressing and positive culture and sensitivity test
from day one to one month after surgery
mortality
Time Frame: from one day to one month after surgery
follow up of patient after surgery (died or not)
from one day to one month after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zagazig University

Investigators

  • Principal Investigator: Reham Zakaria, M.D, Zagazig University, Egypt

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2027

Study Registration Dates

First Submitted

February 19, 2026

First Submitted That Met QC Criteria

February 24, 2026

First Posted (Actual)

February 27, 2026

Study Record Updates

Last Update Posted (Actual)

February 27, 2026

Last Update Submitted That Met QC Criteria

February 24, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2105\17-Feb-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

data will be available on demand by contacting the principle investigator

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Cancer

Clinical Trials on palliative gastric resection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe